Recce Pharmaceuticals (ASX: RCE), who has been pioneering a new class of synthetic anti-infectives, has secured a Trademark Registration for RECCE® by the Canadian Intellectual Property Office.
The International Trademark Registration No. 1289603 officially grants Canada Trademark No. 1225479 for the RECCE® mark, covering a range of pharmaceutical products under Class 5 – including antibiotics and pharmaceutical preparations, and particularly mixed antibiotic preparations for human use.
The significance of this registration is underscored by the growing concern over antimicrobial resistance (AMR) in Canada. With over one-quarter of bacterial infections in the country resistant to first-line antimicrobials, there’s a pressing need for innovative solutions in the pharmaceutical space, and Recce is in a perfect position for it.
“We are pleased to receive this newly registered trademark in Canada, building upon those already registered in the largest pharmaceutical markets of the world,” Recce Pharmaceuticals’ Chief Executive Officer James Graham said.
Recce Pharmaceuticals has also benefited from the Scientific Research & Experimental Development (SR&ED) Tax Incentive program and received two R&D rebates totaling A $275,298. Administered by the Canada Revenue Agency, this program incentivizes businesses to conduct research and development in Canada, fostering innovation and technological advancements.
RCE has been trading at 45.5 cents.